Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • dan
    wiki wiki
    • Jul 2008
    • 194

    Best tool to map 454 reads onto sanger reads?

    I have some very low coverage Sanger sequencing data for a small genome that I would like to try to 'expand' using a higher coverage 454 data set.

    Should I just assemble the 454 reads and map the Sanger sequences onto the contigs?

    Any advantage in trying to map the 454 reads onto the Sanger reads?

    Cheers,
    Dan.
    Homepage: Dan Bolser
    MetaBase the database of biological databases.
  • hlu
    Member
    • Jan 2009
    • 32

    #2
    I suppose that you are trying to do assembly.

    The 454 GS Assembler (newbler) software support hybrid assembly with Sanger + 454 data. You could do one big assembly including all the Sanger and 454 data.

    Comment

    • BaCh
      Member
      • May 2008
      • 81

      #3
      Originally posted by dan View Post
      Should I just assemble the 454 reads and map the Sanger sequences onto the contigs?
      Any advantage in trying to map the 454 reads onto the Sanger reads?
      Unless your existing Sanger consensus hasn't been the work of weeks or months of manual contig joining and finishing, you probably want to do a full de-novo assembly with both the Sanger and the 454 reads.

      I'd take either MIRA (because it has tagging features which point to differences between sequencing technologies) or CABOG for de-novo assembly of 454 and Sanger. Something important to notice: if the DNA used to do the Sanger sequencing and the 454 sdequencing is not 100% the same, you will find some differences between Sanger and 454 which cannot be explained by sequencing errors. Those would be real.

      If you really just want to map to your existing reference, MIRA will also do this happily and even point out all the places where there are differences.

      Regards,
      B.

      PS: Disclaimer: I'm biased regarding MIRA, it's my baby See http://chevreux.org/mira_ex_454sanger.html for an example how a Sanger / 454 hybrid de-novo looks

      Comment

      • dan
        wiki wiki
        • Jul 2008
        • 194

        #4
        Originally posted by BaCh View Post
        PS: Disclaimer: I'm biased regarding MIRA, it's my baby See http://chevreux.org/mira_ex_454sanger.html for an example how a Sanger / 454 hybrid de-novo looks
        Great! Then you're the person to ask... Which is better, MIRA or CABOG? ;-)

        Thanks very much for the infomation above, I'll let you know how I get on.

        Dan.
        Homepage: Dan Bolser
        MetaBase the database of biological databases.

        Comment

        Latest Articles

        Collapse

        • SEQadmin2
          Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
          by SEQadmin2


          Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

          The systematic characterization of the human proteome has
          ...
          07-20-2026, 11:48 AM
        • SEQadmin2
          Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
          by SEQadmin2



          Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
          ...
          07-09-2026, 11:10 AM
        • SEQadmin2
          Cancer Drug Resistance: The Lingering Barrier to Rising Survival
          by SEQadmin2



          Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

          There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
          07-08-2026, 05:17 AM

        ad_right_rmr

        Collapse

        News

        Collapse

        Topics Statistics Last Post
        Started by SEQadmin2, 07-24-2026, 12:17 PM
        0 responses
        30 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-23-2026, 11:41 AM
        0 responses
        23 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-20-2026, 11:10 AM
        0 responses
        212 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-13-2026, 10:26 AM
        0 responses
        78 views
        0 reactions
        Last Post SEQadmin2  
        Working...